Development of agents for the treatment of systemic sclerosis

Expert Opinion on Investigational Drugs

Volumn 10, Issue 7, 2001, Pages 1255-1264

  Herrick, A L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti fibrotics; Antioxidants; Clinical trials; Digital ischaemia; Fibrosis; Immunosuppressants; Raynaud's phenomenon; Scleroderma; Systemic sclerosis; Vascular remodelling; Vasodilators

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; HALOFUGINONE; ILOPROST; LISINOPRIL; LOSARTAN; METHOTREXATE; MONOCLONAL ANTIBODY; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; PROTON PUMP INHIBITOR; QUINAPRIL; RELAXIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT;

ATROPHY; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOLOGY; ISCHEMIA; LETHALITY; NEPHROTOXICITY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; SYSTEMIC SCLEROSIS; ULTRAVIOLET A RADIATION; UPPER GASTROINTESTINAL TRACT; VASCULAR DISEASE;

HUMANS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0034947022     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.7.1255     Document Type: Review

References (78)

1. A disease severity scale for systemic sclerosis: Development and testing
2. Scleroderma and related disorders: Therapeutic aspects
3. Guidelines for clinical trials in systemic sclerosis (scleroderma), I: Disease-modifying interventions
4. Macrovascular disease and systemic sclerosis
5. Reliability of skin involvement measures in scleroderma
6. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis
7. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo controlled trial
8. High-dose versus low dose D-penicillamine in early diffuse systemic sclerosis
9. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma - Preliminary analysis
10. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial
11. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photophoresis)
12. Minocycline in early diffuse scleroderma
13. Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy
14. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma
15. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients
16. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review)
17. Cyclophosphamide therapy for scleroderma
18. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
19. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin)
20. Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controlled trial
21. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
22. Expression of TGF-β 1, -β2 and -β3 in localized and systemic scleroderma
23. TGF-β - A role in systemic sclerosis
24. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts
25. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β
26. Interferon-gamma in the treatment of systemic sclerosis: A randomised controlled multicentre trial
27. Advances in treatment of systemic sclerosis
28. Halofuginone hydrobromide
29. Topical treatment of cutaneous graft versus host disease with halofuginine: A novel inhibitor of collagen Type I synthesis
30. Pulmonary hypertension - Beyond vasodilator therapy
31. Modulation of endothelial gene expression by prostanoids in systemic sclerosis
32. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study
33. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multi-center, placebo-controlled, double-blind study
34. Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis
35. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
36. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
37. Efficacy and safety of UT-15, a prostacyclin analogue, for primary pulmonary hypertension
38. Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension (PAH)
39. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
40. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
41. Cardioreparation with lisinopril in the management of hypertension and heart failure
42. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial
43. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target?
44. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling
45. Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice
46. Localization of endothelin-1 and its binding sites in scleroderma skin
47. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease
48. Immunological study of endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis
49. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
50. Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery
51. Neurohumoral and hemodynamic effects of the selective endothelin antagonist LU 135252 in advanced heart failure
52. Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors
53. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis
54. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin
55. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension
56. Minimising the inhaled dose of NO with breath-to-breath delivery of spikes of concentrated gas
57. Caution with use of inhaled nitric oxide
58. Sustained release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon
59. Skin blood flow after trandermal S-nitrosothio-acetylglucose
60. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud's syndrome: A randomised trial
61. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: Effects of oral L-arginine supplementation
62. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis
63. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon
64. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis
65. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: Clinical trial
66. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and α-tocopherol: An experimental study
67. Vitamin E dietary supplementation inhibits transforming growth factor β1 gene expression in the rat liver
68. The clinical manipulation of angiogenesis: Pathology, side effects, surprises, and opportunities with novel human therapies
69. Clinical trials in coronary angiogenesis: Issues, problems, consensus: An expert panel summary
70. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma
71. Mycophenolate mofetil
72. Biological agents: A novel approach to the therapy of rheumatoid arthritis
73. Etanercept treatment for diffuse scleroderma: A pilot study
74. Hematopoietic stem cell transplantation in rheumatic diseases
75. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation
76. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
77. Induction of immune tolerance to human Type I collagen in patients with systemic sclerosis by oral administration of bovine Type I collagen
78. How can treatment of systemic sclerosis be improved?